Drug Trial Radar · NCT03338816
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Last checked: Nov 20, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Nov 16, 2017
Primary completion
Jan 31, 2019
Study completion May 31, 2021
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Nov 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
Conditions
- Acute Hepatic Porphyria
- Acute Intermittent Porphyria
- Porphyria, Acute Intermittent
- Acute Porphyria
- Hereditary Coproporphyria (HCP)
- Variegate Porphyria (VP)
- ALA Dehydratase Deficient Porphyria (ADP)
Interventions
GivosiranDrug
Givosiran by SC
PlaceboDrug
Matching placebo (normal saline \[0.9% NaCl\]) by SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP)Time frame: 6 months
Locations
36 sites in 18 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Little Rock, Arkansas
Clinical Trial Site
San Francisco, California
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Ann Arbor, Michigan
Clinical Trial Site
New York, New York
Clinical Trial Site
Winston-Salem, North Carolina
Clinical Trial Site
Philadelphia, Pennsylvania
Clinical Trial Site
Galveston, Texas
Clinical Trial Site
Salt Lake City, Utah
Clinical Trial Site
Seattle, Washington
Clinical Trial Site
Auchenflower, Australia
Clinical Trial Site
Camperdown, Australia
Clinical Trial Site
Parkville, Victoria, Australia
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Edmonton, Canada
Clinical Trial Site
Odense, Denmark
Clinical Trial Site
Helsinki, Finland
Clinical Trial Site
Paris, France
Clinical Trial Site
Chemnitz, Germany
Clinical Trial Site
Munich, Germany
Clinical Trial Site
Modena, Italy
Clinical Trial Site
Hamamatsu, Japan
Clinical Trial Site
Iizuka, Japan
Clinical Trial Site
Tokyo, Japan
Clinical Trial Site
Mexico City, Mexico
Clinical Trial Site
Rotterdam, Netherlands
Clinical Trial Site
Warsaw, Poland
Clinical Trial Site
Seoul, South Korea
Clinical Trial Site
Barcelona, Spain
Clinical Trial Site
El Palmar, Spain
Clinical Trial Site
Pamplona, Spain
Clinical Trial Site
Stockholm, Sweden
Clinical Trial Site
Taichung, Taiwan
Clinical Trial Site
Taipei, Taiwan
Clinical Trial Site
Taoyuan City, Taiwan
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.